Beata Sredniawa

Beata Sredniawa

Auto-generated profile, based on publicly available information

Beata Sredniawa

Department of Cardiology and Electrotherapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia Katowice, 41-800 Zabrze, Poland

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GSGerhard Steinbeck
Gerhard Steinbeck
DADietrich Andresen
Dietrich Andresen
KSKarlheinz Seidl
Karlheinz Seidl
JBJohannes Brachmann
Johannes Brachmann
EHEllen Hoffmann
Ellen Hoffmann
JSJochen Senges
Jochen Senges
The rate of death, including sudden cardiac death, is highest early after a myocardial infarction. Yet current guidelines do not recommend the use of an implantable cardioverter–defibrillator (ICD) within 40 days after a myocardial infarction for the prevention of sudden cardiac death. We tested the hypothesis that patients at increased risk who are treated early with an ICD will live longer than those who receive optimal medical therapy alone.

29 August 2015 in EP Europace
Verified
Journal Article
Closed access
SPSilvia G. Priori
Silvia G. Priori
CBCarina Blomström-Lundqvist
Carina Blomström-Lundqvist
Andrea MazzantiAndrea Mazzanti
Andrea Mazzanti
NBNico Blom
Nico Blom
MBMartin Borggrefe
Martin Borggrefe
FZFaiez Zannad
Faiez Zannad

18 October 2022 in EP Europace
Verified
Journal Article
Closed access
PDF file
ZKZbigniew Kalarus
Zbigniew Kalarus
GMGeorges H Mairesse
Georges H Mairesse
ASAdam Sokal
Adam Sokal
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
BŚBeata Średniawa
Beata Średniawa
LELars Eckardt
Lars Eckardt
Atrial fibrillation (AF) is the most common clinical arrhythmia with substantial health and socioeconomic impact on healthcare.1 The number of people affected by this condition was estimated to be 33.5 million in 2010, with an increasing prevalence and incidence over the coming years.2 In 2017, there were 37.6 million [95% confidence interval (CI): 32.5–42.6 million] individuals with AF/atrial flutter globally.3 The estimated number of subjects with AF in 2030 in Europe will be 14–17 million, and the number of new cases of AF per year at 120 000–215 000.4 Atrial fibrillation is independently associated with increased mortality and morbidity from complications such as ischaemic stroke, dementia, and cognitive dysfunction.5 Oral anticoagulation can significantly reduce the risk of stroke, dementia, and death.6 As a part of a holistic or integrated approach to AF care, it is associated with improved outcomes7–9 and is advocated in guidelines.10,11

1 April 2020 in JACC
Verified
Journal Article
Closed access
AMAndrea Mazzanti
Andrea Mazzanti
DGDmitri Guz
Dmitri Guz
ATAlessandro Trancuccio
Alessandro Trancuccio
EPEleonora Pagan
Eleonora Pagan
Deni KukavicaDeni Kukavica
Deni Kukavica
SPSilvia G. Priori
Silvia G. Priori

1 August 2017 in EuroIntervention
Verified
Journal Article
Closed access
MNMarko Noc
Marko Noc
DEDavid Erlinge
David Erlinge
ANAleksandar Neskovic
Aleksandar Neskovic
SKSrdjan Kafedzic
Srdjan Kafedzic
BMBéla Merkely
Béla Merkely
MHMichael Holzer
Michael Holzer
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 March 2009 in International Journal of Cardiology
Verified
Journal Article
Closed access
RLRadoslaw K Lenarczyk
Radoslaw K Lenarczyk
Oskar KowalskiOskar Kowalski
Oskar Kowalski
TKTomasz Kukulski
Tomasz Kukulski
PPPatrycja Pruszkowska-Skrzep
Patrycja Pruszkowska-Skrzep
ASAdam Sokal
Adam Sokal
ZKZbigniew Kalarus
Zbigniew Kalarus